ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $79.00.

ANIP has been the subject of a number of analyst reports. Guggenheim raised their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Finally, StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd.

ANI Pharmaceuticals Stock Up 4.4 %

NASDAQ ANIP opened at $61.40 on Wednesday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market capitalization of $1.29 billion, a P/E ratio of -111.64 and a beta of 0.63. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The stock has a 50 day moving average price of $57.86 and a 200-day moving average price of $58.07.

Insider Activity

In related news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,300 shares of company stock worth $584,869. 12.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. boosted its holdings in ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in ANI Pharmaceuticals by 17.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after purchasing an additional 34,416 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after purchasing an additional 299 shares in the last quarter. Finally, Mizuho Markets Americas LLC acquired a new stake in ANI Pharmaceuticals during the third quarter valued at approximately $11,670,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.